Identification of TCF3-ZNF384 fusion by transcriptome sequencing in B cell acute lymphoblastic leukemia and its laboratory and clinical characteristics.
10.3760/cma.j.cn511374-20200416-00273
- VernacularTitle:转录组测序鉴定
TCF3-ZNF384阳性的急性B淋巴细胞白血病及其实验室及临床特点
- Author:
Qisheng WU
1
;
Fang WANG
;
Junfang YANG
;
Xue CHEN
;
Xiaoli MA
;
Panxiang CAO
;
Yang ZHANG
;
Daijing NIE
;
Jiaqi CHEN
;
Xiaosu ZHOU
;
Jiancheng FANG
;
Mingyue LIU
;
Min ZHANG
;
Ping WU
;
Tong WANG
;
Hongxing LIU
Author Information
1. Department of Pathology and Laboratory Medicine, Beijing Ludaopei Hospital, Beijing 100176, China. starliu@pku.edu.cn.
- Publication Type:Journal Article
- MeSH:
B-Lymphocytes;
Basic Helix-Loop-Helix Transcription Factors/genetics*;
Child;
Hematopoietic Stem Cell Transplantation;
Humans;
Laboratories;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy*;
Trans-Activators/genetics*;
Transcriptome
- From:
Chinese Journal of Medical Genetics
2021;38(4):351-354
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To detect fusion gene with pathological significance in a patient with refractory and relapsed acute B cell lymphoblastic leukemia (B-ALL) and to explore its laboratory and clinical characteristics.
METHODS:Transcriptome sequencing was used to detect potential fusion transcripts. Other laboratory results and clinical data of the patient were also analyzed.
RESULTS:The patient was found to harbor TCF3 exon 17-ZNF384 exon 7 in-frame fusion transcript. The minimal residual disease (MRD) has remained positive after multiple chemotherapy protocols including CD19-, CD22- targeted chimeric antigen receptor T cells immunotherapy. The patient eventually achieved complete remission and sustained MRD negativity after allogeneic hemopoietic stem cell transplantation (allo-HSCT).
CONCLUSION:Transcriptome sequencing can effectively detect potential fusion genes with clinical significance in leukemia. TCF3-ZNF384 positive B-ALL has unique laboratory and clinical characteristics, may not well respond to chemotherapy and immunotherapy, and is more likely to relapse. Timely allo-HSCT treatment may help such patients to achieve long-term disease-free survival. TCF3-ZNF384 positive B-ALL is not uncommon in pediatric patients but has not been effectively identified.
